Met 2024 growth targets for product sales (+13% vs 2023) and total revenues (+10% vs 2023) Strong year-end cash position of €168.3 million ...
Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback